Document:

<PAGE>

                                  EXHIBIT 10.25

                         CONSENT TO ASSIGNMENT AGREEMENT

         THIS CONSENT TO ASSIGNMENT AGREEMENT (this "Agreement") is made
effective and entered into as of June 23, 2000 (the "Effective Date") by and
between GENENTECH, INC., a Delaware corporation, with a principal place of
business at 1 DNA Way, South San Francisco, California 94080 ("Genentech"),
CONNETICS CORPORATION, a Delaware corporation, with a principal place of
business at 3400 Bayshore Road, Palo Alto, California 94303 ("Connetics") and
INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place
of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010
("InterMune"). Genentech, Connetics and InterMune may be referred to herein as a
"Party" or collectively as the "Parties."

                                            RECITALS

     A. WHEREAS, InterMune is a corporation formed for the purpose of research
and development of biopharmaceutical products for the treatment of infectious
and autoimmune diseases;

     B. WHEREAS, Connetics has licensed the rights to certain immunology-based
products and to the technology relating thereto from Genentech pursuant to that
certain License Agreement for Interferon Gamma by and between Connetics and
Genentech, dated May 5, 1998, as amended (the "Genentech License");

     C. WHEREAS, InterMune and Connetics have entered into that certain Amended
and Restated Exclusive Sublicense Agreement, dated April 27, 1999 (the "Original
Agreement"), pursuant to which (a) Connetics granted an exclusive sublicense to
InterMune under the Genentech License to develop, make, have made, import, offer
for sale and sell therapeutic products containing or derived from such
immunology-based products and technology for use for certain specific
indications, and (b) InterMune granted to Connetics the exclusive option to
practice such sublicensed rights in the dermatology field;

     D. WHEREAS, InterMune and Connetics now desire to supersede and replace
the Original Agreement in order to assign to InterMune Connetics' entire right,
title and interest in, to and under the Genentech License by entering into that
certain Assignment and Option Agreement, in the form attached hereto as EXHIBIT
A (the "Assignment Agreement"); and

     E. WHEREAS, pursuant to section 12.4 of the Genentech License, with the
prior written consent of Genentech, Connetics may assign the Genentech License
to InterMune.

         NOW THEREFORE, in consideration of the above recitals and the covenants
set forth herein, the parties hereto agree as follows:

     1. Genentech consents to the assignment by Connetics to InterMune of all
Connetics' right, title and interest in and to the Genentech License.

     2. On the Effective Date, Genentech unconditionally releases and discharges
Connetics from any and all obligations under the Genentech License, and
Genentech deems InterMune to be the successor in interest of Connetics under the
Genentech License. Notwithstanding the above, Connetics shall remain responsible
for all of its obligations, if any, under Section 8.1 of the Genentech License.

     3. InterMune shall assume all of the obligations of and is entitled to all
the rights of Connetics under the Genentech License, except that Connetics shall
remain responsible for all of its obligations, if any, under Section 8.1 of the
Genentech License.

<PAGE>

     4. Section 1.28 of the Genentech License is hereby amended in its entirety
to read as follows:

     "1.28 "Territory" shall mean the United States of America and Canada, and
their respective territories and possessions, and Japan."

     5. Nothing herein shall alter or affect the Stock Agreement or Stock
Agreement Amendment (both defined in the Genentech License) between Connetics
and Genentech.

     6. This agreement may be executed in two or more counterparts, each of
which shall be an original and all of which shall constitute together the same
document.

     7. This agreement shall be governed in accordance with the laws of the
State of California, exclusive of its conflicts of laws provisions.

         IN WITNESS WHEREOF, each of Genentech, Connetics and InterMune have
executed this Agreement, as of the day and year first written above.

INTERMUNE PHARMACEUTICALS, INC.                               GENENTECH, INC.

<TABLE>

<S>                                                           <C>
By: /s/ W. SCOTT HARKONEN                                     By: /s/ ART LEVINSON
   ---------------------------------------                       ---------------------------------------
Print Name: W. Scott Harkonen                                 Print Name: Art Levinson
           -------------------------------                                ------------------------------
Title: Pres. & CEO                                            Title: CEO
      ------------------------------------                           -----------------------------------

CONNETICS CORPORATION
By: /s/ THOMAS G. WIGGANS
    --------------------------------
Print Name: Thomas G. Wiggans
           -------------------------

Title: Pres. & CEO
       -----------------------------

</TABLE><PAGE>

                                  EXHIBIT 10.26

                          REVENUE ADJUSTMENT AGREEMENT

                                 BY AND BETWEEN

                         INTERMUNE PHARMACEUTICALS, INC.

                                       AND

                              CONNETICS CORPORATION

                                  JUNE 27, 2000

<PAGE>

                          REVENUE ADJUSTMENT AGREEMENT

         THIS REVENUE ADJUSTMENT AGREEMENT (the "Agreement") is made effective
and entered into as of June 27, 2000 (the "Effective Date") by and between
CONNETICS CORPORATION, a Delaware corporation, with its principal place of
business at 3400 West Bayshore Road, Palo Alto, CA 94303 ("Connetics"), and
INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with its principal
place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010
("InterMune"). Connetics and InterMune may be referred to herein as a "Party" or
collectively as the "Parties."

                                            RECITALS

A.       WHEREAS, the Parties have entered into that certain Collaboration
         Agreement, dated as of April 27, 1999 (the "Collaboration Agreement"),
         by which, among other provisions, InterMune became obligated to pay to
         Connetics: (i) a $500,000 milestone payment on or before March 31,
         2001; and (ii) a $1.5 million milestone payment on or before March 31,
         2002;
B.       WHEREAS, The Parties have entered into that certain Assignment and
         Option Agreement, dated as of June 23, 2000 (the "Assignment
         Agreement"), pursuant to which, among other provisions: (i) Connetics
         assigned to InterMune Connetics' entire right, title and interest in,
         to and under that certain License Agreement for Interferon Gamma by and
         between Connetics and Genentech, Inc. ("Genentech") dated May 5, 1998,
         as amended (the "Genentech License") and (ii) InterMune affirmed its
         obligation to pay to Connetics the $1.5 million milestone payment
         pursuant to the Collaboration Agreement;
C.       WHEREAS, the Parties have entered into that certain Transition
         Agreement, dated as of April 27, 1999 (the "Transition Agreement"), by
         which, among other provisions, the parties have set forth certain
         rights and obligations with respect to the revenue from the sales of
         Actimmune-Registered Trademark-; and
D.       WHEREAS, by this Amendment, the Parties now desire to delete Section
5.2 of the Assignment Agreement and terminate the Collaboration Agreement and
Transition Agreement (each generically, an "Original Agreement," and
collectively, the "Original Agreements") as set forth herein in order to adjust
the Parties' rights and obligations with respect to the revenue from the sales
of Actimmune.

         NOW, THEREFORE, in consideration of the foregoing recitals and mutual
promises hereinafter set forth, the Parties agree as follows:

1.       DEFINITIONS.

         1.1      ACTIMMUNE. "Actimmune" means the filled and finished form
of the protein encoded by the interferon gamma-1b gene, and sold and
distributed under the trademark ACTIMMUNE-Registered Trademark-, which is
owned by Genentech and licensed to Connetics and its sublicenses under the
Genentech License.

         1.2      ACTIMMUNE GROSS MARGIN. "Actimmune Gross Margin" means
Actimmune Net Sales less all applicable Product Cost of Actimmune Units sold,
GNE Royalties, third party royalties payable pursuant to Section 8.4 of the
Genentech License and CORD Distribution Costs.

         1.3      ACTIMMUNE GROSS SALES. "Actimmune Gross Sales" means all
revenue recorded in connection with shipments of Actimmune Units multiplied by
the price per Actimmune Unit, including revenue with associated accounts
receivable for accounting purposes for specific shipment/invoicing transactions
with respect to Actimmune Units, and assumes that invoices are prepared
immediately following notification of shipment of goods, and are dated the same
day of shipment.

         1.4      ACTIMMUNE NET SALES. "Actimmune Net Sales" means Actimmune
Gross Sales less adjustments for the following: product returns, Medicare and
Medicaid reimbursements, chargebacks, rebates, state payments, other contractual
reimbursement, and cash discounts.

                                       1
<PAGE>
         1.5      ACTIMMUNE UNITS. "Actimmune Units" means vials of ACTIMMUNE(R)
that are sold as commercial product by InterMune in an arm's length transaction.

         1.6      CORD DISTRIBUTION COSTS. "CORD Distribution Costs" means the
actual payment by InterMune to CORD Logistics, Inc., for distribution services
for sales of Actimmune.

         1.7      GNE ROYALTIES. "GNE Royalties" means the amount of royalties
payable to Genentech, Inc. pursuant to section 8.3 of the Genentech License for
Actimmune Net Sales.

         1.8      PRODUCT MANAGEMENT COSTS. "Product Management Costs" means
InterMune's actual costs to manage sales of Actimmune Units, including all
expenses and services related to sales of such Actimmune Units, such as
maintenance of safety databases, etc., tracked on a regular basis and properly
accounted for.

2.       AMENDMENT OF ASSIGNMENT AGREEMENT.

         Section 5.2 of the Assignment Agreement is deleted in its entirety.
Section 5.1 of the Assignment Agreement is unaffected by this Agreement.

3.       TERMINATION OF COLLABORATION AGREEMENT.

         The Collaboration Agreement is terminated in its entirety.

4.                           TERMINATION OF TRANSITION AGREEMENT.

         The Transition Agreement is terminated in its entirety.

5.       INTERMUNE PAYMENTS TO CONNETICS.

         5.1      JUNE 30, 2000. On June 30, 2000, InterMune shall be obligated
to pay and shall pay $5,218,172 to Connetics; provided however, InterMune shall
be credited $484,305 toward this payment.

         5.2      MARCH 31, 2001. On March 31, 2001, InterMune shall pay
$942,478 to Connetics.

6.       REVENUE RECOGNITION.

         For the fiscal quarter beginning April 1 and ending June 30, 2000, and
without regard to the Effective Date of this Agreement, InterMune shall be
entitled to book and recognize Actimmune Net Sales for sales of all Actimmune
Units and the Actimmune Gross Margin. Effective July 1, 2000, InterMune shall be
entitled to book and recognize all revenues, sales, margins, etc. from the sales
of Actimmune.

7.       OBLIGATIONS TO THIRD PARTIES AND INDEMNIFICATION OF CONNETICS.

         InterMune hereby affirms its obligations pursuant to Section 2.5 of the
Transition Agreement and Section 5.4 of the Assignment Agreement to remit to
Genentech any accounts payable on Actimmune Net Sales for third-party royalties
and for GNE Royalties, all as required by the Genentech License. InterMune
affirms its covenant and agreement to remit the full amount of such royalties
directly to Genentech or the applicable third party, and shall indemnify

                                       2
<PAGE>

Connetics against any action by Genentech or such third party to collect
royalties for Actimmune Unit Sales made after April 27, 1999.

8.       CONFIDENTIALITY.

         8.1      CONFIDENTIAL INFORMATION OBLIGATIONS. As used herein,
"Confidential Information" means all information that a Party discloses to the
other Party under this Agreement or had disclosed to the other Party under the
Original Agreement, provided that Confidential Information shall not include
such information excluded under Section 8.2. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing by the Parties, each
Party agrees that, during the term of this Agreement and for five (5) years
after the expiration or termination of this Agreement, it shall keep
confidential and shall not publish or otherwise disclose and shall not use for
any purpose other than as provided for in this Agreement any Confidential
Information furnished to it by the other Party pursuant to this Agreement, the
Collaboration Agreement and/or the Transition Agreement.

         8.2      EXCEPTIONS. The obligations set forth in Section 8.1 shall not
apply to any Information that the receiving Party can demonstrate by competent
evidence:

                  (a)      was already known to the receiving Party, other
than under an obligation of confidentiality, at the time of disclosure by the
other Party;

                  (b)      was generally available to the public or otherwise
part of the public domain at the time of its disclosure to the receiving
Party by the other Party;

                  (c)      became generally available to the public or
otherwise part of the public domain after its disclosure and other than
through any act or omission of the receiving Party in breach of this
Agreement;

                  (d)      was disclosed to the receiving Party, other than
under an obligation of confidentiality to a third party, by a third party who
had no obligation to the disclosing Party not to disclose such information to
others; or

                  (e)      is independently developed by the receiving Party
without using any of the other Party's Confidential Information.

         8.3 TERMS OF THE AGREEMENT. The Parties agree that the terms of this
Agreement will be considered Confidential Information of both Parties.
Notwithstanding the foregoing, a Party shall have the right to disclose the
material financial terms of the Agreement to any bona fide potential investor,
investment banker, acquirer, merger partner or other potential financial
partner, subject to such Party obtaining the agreement of such party receiving
such Confidential Information to keep such information confidential.

         8.4 PERMITTED DISCLOSURE. Notwithstanding the limitations in this
Section 8, each Party may disclose Confidential Information belonging to the
other Party (or otherwise subject to this Section 8), to the extent such
disclosure is reasonably necessary in the following instances, but solely for
the limited purpose of such necessity:

                  (a)      filing or prosecuting patents;

                  (b)      regulatory and tax filings;

                  (c)      prosecuting or defending litigation;

                                       3
<PAGE>

                  (d)      complying with applicable governmental laws or
regulations or valid court orders; and

                  (e)      disclosure to a party's affiliates, licensees,
sublicensees, employees, consultants or agents who agree to be bound by similar
terms of confidentiality and non-use at least equivalent in scope to those set
forth in this Article 8.

         Notwithstanding the foregoing, in the event a Party is required to make
a disclosure of the other Party's Confidential Information pursuant to this
Section 8.4, it will give reasonable advance notice to the other Party of such
disclosure and endeavor in good faith to secure confidential treatment of such
information. In any event, the Parties agree to take all reasonable action to
avoid disclosure of Confidential Information hereunder. Further, the Parties
agree to consult with one another on the provisions of this Agreement to be
redacted in any filings made by a Party with the United States Securities and
Exchange Commission or as otherwise required by law.

9.       TERMINATION

         9.1 TERM OF AGREEMENT. The term of this Agreement shall expire upon
InterMune's payment of the full amounts to Connetics pursuant to Sections 5.1
and 5.2.

         9.2 TERMINATION FOR MATERIAL BREACH. If either Party shall default in a
material manner with respect to any material provision of this Agreement and the
other Party shall have given the defaulting Party written notice of such
default, the defaulting Party shall have thirty (30) days to cure such default.
If such default is not cured within such thirty (30) day period, the
non-defaulting Party shall have the right, upon notice to the defaulting Party
and without prejudice to any other rights the non-defaulting Party may have, to
terminate this Agreement unless the defaulting Party is in the process of
attempting in good faith to remedy such default, in which case, the thirty (30)
day cure period shall be extended by an additional thirty (30) days.

         9.3      SURVIVING RIGHTS. The obligations and rights of the Parties
under Sections 7, 8, 9, 10.3, 10.6, 10.7, and 10.11 shall survive any
termination or expiration of the Agreement.

         9.4      ACCRUED RIGHTS AND SURVIVING OBLIGATIONS. The termination or
expiration of the Agreement for any reason shall be without prejudice to any
rights which shall have accrued to the benefit of either Party prior to such
termination or expiration, including any damages arising from any breach
hereunder. Such termination or expiration shall not relieve either Party from
obligations, which are expressly indicated to survive termination or expiration
of the Agreement.

         9.5      BANKRUPTCY RIGHTS. In the event that this Agreement is
terminated or rejected by a Party or its receiver or trustee under applicable
bankruptcy laws due to such Party's bankruptcy, then all rights and licenses
granted under or pursuant to this Agreement by such Party to the other Party
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code and any similar law or regulation in any other country, licenses
of rights to "intellectual property" as defined under Section 101(52) of the
Bankruptcy Code.

10.      MISCELLANEOUS.

         10.1     WAIVER. No waiver by either Party hereto of any breach or
default of any of the covenants or agreements herein set forth shall be deemed a
waiver as to any subsequent or similar breach or default.

         10.2     ASSIGNMENT. This Agreement shall be binding upon and inure to
the benefit of the Parties hereto and their permitted successors and assigns;
provided, however, that InterMune

                                       4
<PAGE>

may not assign any of its rights and obligations hereunder without the prior
written consent of Connetics, except as incident to the merger,
consolidation, reorganization or acquisition of stock or assets affecting
substantially all of the assets or actual voting control of InterMune. Any
assignment or attempted assignment by InterMune in violation of the terms of
this Section 10.2 shall be null and void and of no legal effect.

         10.3     NOTICES. Any notice or other communication required or
permitted to be given to either Party hereto shall be in writing and shall be
deemed to have been properly given and to be effective on the date of delivery
if delivered in person or by facsimile or five (5) days after mailing by
registered or certified mail, postage paid, to the other Party at the following
address:

<TABLE>

<S>                                              <C>
         In the case of InterMune:               InterMune Pharmaceuticals, Inc.
                                                 1710 Gilbreth Road,
                                                 Suite 301
                                                 Burlingame, CA 94010
                                                 Fax: (650) 259-0774
                                                 Attention:  General Counsel

         with a copy to:                         Cooley Godward LLP
                                                 Five Palo Alto Square
                                                 3000 El Camino Real
                                                 Palo Alto, CA 94306
                                                 Fax: (650) 849-7400
                                                 Attention:  Barclay Kamb

         In the case of Connetics:               Connetics Corporation
                                                 3400 West Bayshore Road
                                                 Palo Alto, CA 94303
                                                 Fax: (650) 843-2899
                                                 Attention:  General Counsel

</TABLE>

Either Party may change its address for communications by a notice to the other
Party in accordance with this Section.

         10.4HEADINGS. The headings of the several sections are inserted for
convenience of reference only and are not intended to be a part of or to affect
the meaning or interpretation of this Agreement.

         10.5AMENDMENT. No amendment or modification hereof shall be valid or
binding upon the Parties unless made in writing and signed by both Parties.

         10.6     GOVERNING LAW. This Agreement shall be governed exclusively by
the laws of the State of California as such law applies to contracts entered
into between and to be performed by California residents entirely in the State
of California.

         10.7     DISPUTE RESOLUTION.

                  (a)      In the event of any controversy or claim arising out
of, relating to or in connection with any provision of this Agreement, or the
rights or obligations of the Parties hereunder, the Parties shall try to settle
their differences amicably between themselves by referring the disputed matter
to the President of InterMune and the Chief Executive Officer of Connetics for
discussion and resolution. Either Party may initiate such informal dispute
resolution by sending written notice of the dispute to the other Party, and
within ten (10) days after such notice such representatives of the Parties shall
meet for attempted resolution by good faith negotiations. If such personnel are
unable to resolve such dispute within thirty (30) days of

                                      5
<PAGE>

initiating such negotiations, either Party may seek to have such dispute
resolved by binding arbitration under this Section 10.7. The arbitration
shall be held in Palo Alto, California according to the Commercial
Arbitration Rules of the American Arbitration Association (the "Rules"). The
arbitration will be conducted by a panel of three (3) arbitrators who are
knowledgeable in the subject matter that is at issue in the dispute, are not
affiliated directly or indirectly with either Party, and are selected by
mutual agreement of the Parties. Failing such agreement, the arbitrators
shall be selected appointed as provided in the Rules. During the arbitration,
the Parties shall have such discovery rights as the arbitrators may allow,
consistent with the discovery permitted by the Federal Code of Civil
Procedure. In conducting the arbitration, the arbitrators shall apply the
rules of evidence applicable in California, and shall be able to decree any
and all relief of an equitable nature, including but not limited to such
relief as a temporary restraining order, a preliminary injunction, a
permanent injunction, or replevin of property, as well as specific
performance. The arbitrators shall also be able to award direct and indirect
damages, but shall not award any other form of damage (e.g., punitive or
exemplary damages). The reasonable fees and expenses, of the arbitrators,
along with the reasonable legal fees and expenses of the prevailing Party
(including all expert witness fees and expenses), the fees and expenses of a
court reporter, and any expenses for a hearing room, shall be paid as
follows: If the arbitrators rule in favor of one Party on all disputed issues
in the arbitration, the losing Party shall pay one hundred percent (100%) of
such fees and expenses; if the arbitrators rule in favor of one Party on some
issues and the other Party on other issues, the arbitrators shall issue with
the rulings a written determination as to how such fees and expenses shall be
allocated between the Parties. The arbitrators shall allocate fees and
expenses in a way that bears a reasonable relationship to the outcome of the
arbitration, with the Party prevailing on more issues, or on issues of
greater value or gravity, recovering a relatively larger share of its legal
fees and expenses. The decision of the arbitrators shall be final and may be
entered, sued on or enforced by the Party in whose favor it runs in any court
of competent jurisdiction at the option of such Party. Whether a claim,
dispute or other matter in question would be barred by the applicable statute
of limitations, which statute of limitations also shall apply to any claim or
disputes subject to arbitration under this Section, shall be determined by
binding arbitration pursuant to this Section.

                  (b)      Notwithstanding anything to the contrary in this
Agreement, either Party may (without resort to arbitration) seek immediate
injunctive or other interim relief from any court of competent jurisdiction with
respect to any breach of Section 9 hereof, or as necessary to enforce and
prevent infringement of the patent rights, copyright rights, trademarks, trade
secrets, or other intellectual property rights owned or controlled by a Party or
its Affiliates.

         10.8 FORCE MAJEURE. Any delays in performance by any Party under this
Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the Party
affected, including but not limited to acts of God, embargoes, governmental
restrictions, fire, flood, explosion, riots, wars, civil disorder, rebellion or
sabotage. The Party suffering such occurrence shall immediately notify the other
Party as soon as practicable, and any time for performance hereunder shall be
extended by the actual time of delay caused by the occurrence.

         10.9 SEVERABILITY. If any part of this Agreement is declared invalid by
any legally governing authority having jurisdiction over either Party, then such
declaration shall not affect the remainder of the Agreement and the Parties
shall revise the invalidated part in a manner that will render such provision
valid without impairing the Parties' original interest.

         10.10 CUMULATIVE RIGHTS. The rights, powers and remedies hereunder
shall be in addition to, and not in limitation of, all rights, powers and
remedies provided at law or in equity,

                                       6
<PAGE>

or under any other agreement between the Parties. All of such rights, powers
and remedies shall be cumulative, and may be exercised successively or
cumulatively.

         10.11 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

         10.12 ENTIRE AGREEMENT. This Agreement embodies the entire
understanding of the Parties with respect to the subject matter hereof and
supersedes and terminates all previous communications, representations or
understandings, either oral or written, between the Parties relating to the
subject matter hereof.

                                       7
<PAGE>

         IN WITNESS WHEREOF, both InterMune and Connetics have executed this
Agreement, as of the day and year first written above.

<TABLE>
<CAPTION>

<S>                                                  <C>
INTERMUNE PHARMACEUTICALS, INC.                      CONNETICS CORPORATION

By: /s/ W. SCOTT HARKONEN                            By: /s/ THOMAS G. WIGGANS
   --------------------------------------                --------------------------------------
Print Name: W. Scott Harkonen                        Print Name: Thomas G. Wiggans
            -----------------------------                        ------------------------------
Title: Pres. & CEO                                   Title: Pres. & CEO
       ----------------------------------                   -----------------------------------
</TABLE>

                                  EXHIBIT 10.27
                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]